Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Chang Kyun | - |
dc.contributor.author | Kim, Hyun-Soo | - |
dc.contributor.author | Ye, Byong Duk | - |
dc.contributor.author | Lee, Kang-Moon | - |
dc.contributor.author | Kim, You Sun | - |
dc.contributor.author | Rhee, Sang Youl | - |
dc.contributor.author | Kim, Hyo-Jong | - |
dc.contributor.author | Yang, Suk-Kyun | - |
dc.contributor.author | Moon, Won | - |
dc.contributor.author | Koo, Ja-Seol | - |
dc.contributor.author | Lee, Suck-Ho | - |
dc.contributor.author | Seo, Geom Seog | - |
dc.contributor.author | Park, Soo Jung | - |
dc.contributor.author | Choi, Chang Hwan | - |
dc.contributor.author | Jung, Sung-Ae | - |
dc.contributor.author | Hong, Sung Noh | - |
dc.contributor.author | Im, Jong Pil | - |
dc.contributor.author | Kim, Eun Soo | - |
dc.date.available | 2020-11-02T18:43:21Z | - |
dc.date.issued | 2014-05-01 | - |
dc.identifier.issn | 1873-9946 | - |
dc.identifier.issn | 1876-4479 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/9312 | - |
dc.description.abstract | Background/aims: The effect of immunosuppressants on the efficacy of a variety of vaccines is a controversial issue in patients with inflammatory bowel disease (IBD). In this study we determined whether specific imnnunosuppressants impair the serological response to the standard 23-valent pneumococcal polysaccharide vaccine (PPSV23) in a large cohort of patients with Crohn's disease (CD). Methods: This was a multi-center, prospective observational study of adult patients with CD at 15 academic teaching hospitals in Korea. The study population received one intramuscular injection of PPSV23. Anti-pneumococcal IgG antibody titers were measured by immunoassay prior to and 4 weeks after vaccination. All vaccination-related adverse events and the effect of the vaccine on disease activity were also evaluated. Results: The overall serological response rate was 67.5% (133/197). The serological response rate was significantly lower in patients on anti-tumor necrosis factor (anti-TNF) therapy (50.0% on anti-TNF atone; 58.0% on anti-TNF combined with an immunomodulator, IM) than patients on 5-aminosalicylate (78.4%; all P-values vs. 5-aminosalicylate < 0.05); 45.6% (41/90) of patients on anti-TNF therapy were not protected against PPSV23. IM did not affect the immunologic response to the vaccine. Female gender and anti-TNF therapy were significant predictors of non-response to the vaccine (odds ratio [OR] 2.316, P = 0.015; OR 2.582, P = 0.048, respectively). Vaccination was generally safe and tolerated by all patients. Conclusions: Patients with CD on anti-TNF therapy are at significant risk of an inadequate response to PPSV23. The pneumococcal vaccination strategy should be optimized for patients with CD on anti-TNF therapy. (C) 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.title | Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.crohns.2013.09.022 | - |
dc.identifier.scopusid | 2-s2.0-84897413269 | - |
dc.identifier.wosid | 000335280700007 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CROHNS & COLITIS, v.8, no.5, pp 384 - 391 | - |
dc.citation.title | JOURNAL OF CROHNS & COLITIS | - |
dc.citation.volume | 8 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 384 | - |
dc.citation.endPage | 391 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | IMMUNE-RESPONSE | - |
dc.subject.keywordPlus | IMMUNOSUPPRESSION | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | INFLIXIMAB | - |
dc.subject.keywordPlus | KNOWLEDGE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | ADULTS | - |
dc.subject.keywordPlus | IBD | - |
dc.subject.keywordAuthor | Crohn's disease | - |
dc.subject.keywordAuthor | Inflammatory bowel disease | - |
dc.subject.keywordAuthor | Innnnunosuppressive agents | - |
dc.subject.keywordAuthor | Pneumococcal vaccine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.